What a peptide–protein interaction workflow has to decide before any docking runs
Peptide Order Supplier Geo Peptides The workflow’s governing rule is that a stage may only pass forward what the next stage can falsify. Everything else in this article is that rule applied four times.
Handoff checks can expose missing evidence before experiments, but this article does not measure the distribution of campaign failures. Review sequence assignments, search settings, pose assumptions, material identity and assay controls together.
The tool question comes second, and it is a question about prior knowledge rather than accuracy. Peptide docking was first assessed in CAPRI in rounds 28 そして 29, and the assessment that followed argued that the existing criteria needed better selection rules, particularly where the binding site is unknown (the CAPRI peptide rounds). That is the honest state of the field: methods are benchmarked, criteria are contested, and no paper recommends a default method for a given use case. So the decision you actually make before docking is which hand-off criteria your campaign needs.
重要なポイント: A stage may only pass forward what the next stage can falsify.
ステップ 1: Define the library by diversity sampling, not by enumeration
Input: the biological question, stated as a comparison you intend to make. アクション: fix length, residue alphabet, offset and controls. Output: a design record that a synthesis team can build from without asking you anything. Done when the design record states why this library answers this question and what it deliberately does not cover.
Exhaustive coverage is not available, and the sequence-space arithmetic settles the argument quickly. A 7-mer space holds 1.28×10⁹ sequences, a 10-mer 1.024×10¹³, and a 15-mer 3.2768×10¹⁹, against a practical display-library ceiling around 10⁹ members (sequence-space arithmetic). That ceiling is an order-of-magnitude convention, not a measured limit, but the conclusion holds at any plausible value: past roughly six or seven residues you are sampling, not enumerating.
This is where diversity-sampling peptidomics earns its place. You choose a panel that spans the chemical and structural variety of the source peptides rather than one peptide per detected feature, and you say so in the design record. A library-design principle stated in our own service documentation puts the failure mode plainly: a peptide library can fail long before synthesis Geopeptides 環状ペプチドのサプライヤー starts if the design does not match the biological question. Length, 重なり合う, residue alphabet and mutation scope all drive peptide count, synthesis complexity and assay throughput, which is why peptide library design should not stop at sequence selection. Controls belong in the same record: a known binder, a scrambled version, and a peptide you expect to fail.
ステップ 2: Run analytical screening and hand over a peptide table with provenance
Input: raw LC-MS/MS files and the sample-handling record. アクション: search without enzyme specificity, with expanded variable modifications and target-decoy FDR control. Output: a peptide table carrying its own provenance. Done when a docking team can filter, re-rank and defend the list without opening a single raw file. 環状ペプチドファクトリー
Set and assess false-discovery control for the actual peptidomics workflow. A study-specific combination of peptide and protein filters cannot guarantee less than 1% peptide FDR in another dataset, particularly in searches without enzyme specificity or with expanded modifications. Parabolic Peptides
The reporting template already exists. The MIAIPE reporting checklist, developed under HUPO for immunopeptidomics, requires stating whether identification was sequence-based or de novo, the peak-list tool and its parameters, the search engine settings, and every filter applied (the MIAIPE reporting checklist). Borrow its structure even for a non-immunological sample. One more field is easy to forget: the generic peptidomics analytical workflow runs from sample pre-treatment through extraction, fractionation, MS analysis and identification, and extraction has to be fast enough to avoid ongoing enzymatic degradation. Peptides present in the sample is a measurement with a handling history, so record it.
ステップ 3: Prioritize with docking, and read the score as a rank rather than an affinity
Input: the peptide table. アクション: choose a protocol by peptide length, receptor state and whether you have prior site information. Output: a ranked pose table with the protocol and criterion recorded. Done when every row states which protocol produced it and which success criterion was applied.
The published success rates disagree, and the disagreement is informative. HADDOCK’s peptide protocol, starting from a three-conformation ensemble, 到達した 79.4% acceptable models for bound receptor against unbound peptide and 69.4% for unbound/unbound (HADDOCK’s peptide protocol). HPEPDOCK’s blind-mode benchmark reports 33.3% top-10 success on 57 unbound cases, に上昇する 72.6% when the binding site is supplied (HPEPDOCK’s blind-mode benchmark). A re-benchmark of peptide docking methods puts CABS-dock at 53.0% bound and 37.0% unbound on peptiDB, and AutoDock CrankPep at 85.7% on LEADS-PEP under a tighter RMSD cutoff in local mode (a re-benchmark of peptide docking methods). AlphaFold2’s peptide results run 75% within 1.5 Å when a binding motif is known and 36% within 2.5 Å when it is not (AlphaFold2’s peptide results).
Those numbers are not a league table. They differ in dataset, peptide length and success criterion, and the spread reflects the criteria as much as the methods. What does transfer is the direction of the effects. Blind docking is a harder question than site-directed docking, which is why HADDOCK is information-driven docking: ambiguous interaction restraints from mutagenesis, MS, NMR or conservation encode what you already know (HADDOCK is information-driven docking). CABS-dock runs blind, taking the peptide as fully flexible and returning trajectories to cluster rather than one ranked pose (CABS-dock runs blind). AlphaFold 3’s own evaluation reports protein and antibody interfaces and states that it predicts static structures, not ensembles (AlphaFold 3’s own evaluation). Choose the protocol that matches the prior knowledge you have, then read the output as a rank.
ステップ 4: Judge the pose with quality classes, then decide what deserves synthesis
DockQ evaluates a predicted complex against a reference structure and is useful for retrospective benchmarking. It cannot supply a measured quality band for a novel complex whose reference is unknown. For prospective selection, use calibrated confidence evidence, diversity, feasibility and a predefined experimental validation plan. DockQ method.
<図形クラス="ブログチャート" スタイル="最大幅:640ピクセル;マージン:1.5レムオート;フォントサイズ:12ピクセル;行の高さ:1.3;色:継承する"> <svg viewBox="0 0 560 380" スタイル="最大幅: 100%; 身長: 自動; フォントファミリー: 「インター」, システムUI, サンセリフ; 色: #1e293b; --チャートミュート: #64748b;" 役割="画像" aria-labeledby="dockq-class-cutoffs-on-a-0-1-scale-title dockq-class-cutoffs-on-a-0-1-scale-desc"> <スタイル> /* レンダラは、要素の背景が黒の iframe にグラフを配置します。, iframe はチャートとは異なる形状です, そのため、レターボックスのバンドが周囲の黒い枠として表示されました (プロッド 09-22). iframe 内のドキュメントはデフォルトで透明です; ここにペイントすると要素の背景がカバーされます, 代わりにチャートがインライン化されている場合、これは何も一致しません. このブロックには山かっこを入れないでください: SVG 内のスタイル要素は外部コンテンツとして解析されます, したがって、1 つの浮遊括弧はその中のすべてのルールを破棄します. */ html, 体 { 背景: #ふふふふ; マージン: 0; } @メディア (縮小モーションを好む: 減らす) { * { アニメーション: なし !重要; 遷移: なし !重要; } } </スタイル> <長方形 x="0" y="0" 幅="560" 身長="380" rx="8" 塗りつぶし="#ふふふふ" /> <タイトルID="dockq-class-cutoffs-on-a-0-1-scale-title">DockQ class cutoffs on a 0-1 規模</タイトル> <説明ID="dockq-class-cutoffs-on-a-0-1-scale-desc">DockQ class cutoffs on a - 規模: values for Incorrect, Acceptable, 中くらい, 高い. DockQ class cutoffs on a 0-1 規模. ラインデータ: Incorrect 0.23; Acceptable 0.49; 中くらい 0.8; High 1.Source: Basu & Wallner, PLoS ONE 11(8):e0161879 2016.</説明> <テキストx="280.0" y="29" テキストアンカー="真ん中" フォントサイズ="18" フォントの太さ="800" 塗りつぶし="現在の色">DockQ class cutoffs on a 0-1 規模</文章> <行 x1="70" y1="292.0" x2="500" y2="292.0" ストローク="現在の色" 不透明度="0.08" /> <行 x1="70" y1="239.5" x2="500" y2="239.5" ストローク="現在の色" 不透明度="0.08" /> <行 x1="70" y1="187.0" x2="500" y2="187.0" ストローク="現在の色" 不透明度="0.08" /> <行 x1="70" y1="134.5" x2="500" y2="134.5" ストローク="現在の色" 不透明度="0.08" /> <行 x1="70" y1="82.0" x2="500" y2="82.0" ストローク="現在の色" 不透明度="0.08" /> <テキストx="64" y="296.0" テキストアンカー="終わり" フォントサイズ="10" 塗りつぶし="現在の色" 不透明度="0.7">0</文章> <テキストx="64" y="243.5" テキストアンカー="終わり" フォントサイズ="10" 塗りつぶし="現在の色" 不透明度="0.7">0.25</文章> <テキストx="64" y="191.0" テキストアンカー="終わり" フォントサイズ="10" 塗りつぶし="現在の色" 不透明度="0.7">0.5</文章> <テキストx="64" y="138.5" テキストアンカー="終わり" フォントサイズ="10" 塗りつぶし="現在の色" 不透明度="0.7">0.75</文章> <テキストx="64" y="86.0" テキストアンカー="終わり" フォントサイズ="10" 塗りつぶし="現在の色" 不透明度="0.7">1</文章> <polyline points="70.0,243.7 213.3,189.1 356.7,124.0 500.0,82.0" 塗りつぶし="なし" ストローク="#f97316" ストローク幅="2.5" stroke-linecap="round" stroke-linejoin="round" /> <サークルcx="70.0" cy="243.7" r="4" 塗りつぶし="#f97316" /> <テキストx="70.0" y="234.7" テキストアンカー="真ん中" フォントサイズ="9" 塗りつぶし="現在の色">0.23</文章> <テキストx="70.0" y="312.0" テキストアンカー="真ん中" フォントサイズ="10" 塗りつぶし="現在の色" 不透明度="0.8"><ツパン x="70.0" ディ="0">Incorrect</ツパン></文章> <サークルcx="213.3" cy="189.1" r="4" 塗りつぶし="#38bdf8" /> <テキストx="213.3" y="180.1" テキストアンカー="真ん中" フォントサイズ="9" 塗りつぶし="現在の色">0.49</文章> <テキストx="213.3" y="312.0" テキストアンカー="真ん中" フォントサイズ="10" 塗りつぶし="現在の色" 不透明度="0.8"><ツパン x="213.3" ディ="0">Acceptable</ツパン></文章> <サークルcx="356.7" cy="124.0" r="4" 塗りつぶし="#a78bfa" /> <テキストx="356.7" y="115.0" テキストアンカー="真ん中" フォントサイズ="9" 塗りつぶし="現在の色">0.8</文章> <テキストx="356.7" y="312.0" テキストアンカー="真ん中" フォントサイズ="10" 塗りつぶし="現在の色" 不透明度="0.8"><ツパン x="356.7" ディ="0">中くらい</ツパン></文章> <サークルcx="500.0" cy="82.0" r="4" 塗りつぶし="#22c55e" /> <テキストx="500.0" y="73.0" テキストアンカー="真ん中" フォントサイズ="9" 塗りつぶし="現在の色">1</文章> <テキストx="500.0" y="312.0" テキストアンカー="真ん中" フォントサイズ="10" 塗りつぶし="現在の色" 不透明度="0.8"><ツパン x="500.0" ディ="0">高い</ツパン></文章> <テキストx="280.0" y="366" テキストアンカー="真ん中" フォントサイズ="10" 塗りつぶし="私たちの(--チャートミュート, 現在の色)">ソース: Basu & Wallner, PLoS ONE 11(8):e0161879 (2016)</文章> </SVG> </形>
The specification is where computational and experimental teams usually lose each other. Name the exact sequence version, the modification and its site, そして対イオンの形, because a change in any of them changes what you are testing. Ask for a certificate of analysis with analytical-HPLC purity, mass-spectrometry identity and net peptide content, and add endotoxin testing or counter-ion analysis where the assay needs it. A supplier such as 商船三井の変更点 can deliver that package alongside the peptide, which is the practical reason to settle the data requirements before the order rather than after it.
ステップ 5: Confirm experimentally, matching the assay to the question asked
Input: the synthesized peptides and their lot data. アクション: run an assay whose readout answers the specific question. Output: a binding or no-binding result with its measurement conditions. Done when the result can be compared to the docking prediction on terms both sides accept.
Match the assay to the claim. A docking pose predicts a binding site and an approximate geometry; a competition assay or a mutagenesis series tests the site, while a direct binding measurement tests affinity. They are not interchangeable, and a null result from the wrong assay tells you nothing about the pose. The SKEMPI affinity database shows why the method has to travel with the number: its entries record the measurement method and temperature, and surface plasmon resonance and fluorescence spectroscopy dominate the literature (the SKEMPI affinity database). Any “typical Kd” you compare against inherits the biases of those two methods, so report your own conditions and compare like with like.
A confirmed binder supports the binding hypothesis, but does not prove the predicted pose or validate an entire docking protocol. Nonbinding and weak-binding results are both informative when assay sensitivity, material quality and conditions are understood.
Common failure points and how to catch them at the hand-off
The pattern behind the table is that each failure is cheap to catch upstream and expensive downstream. A peptide table without its FDR settings cannot be re-filtered, so the docking team either trusts it or rebuilds it. A ranked list without its protocol cannot be interpreted, so a good pose and a lucky pose look identical. A specification missing the counterion form produces a peptide that may behave differently from the one modelled.
結論
That rule also tells you how to scope a campaign or judge a partner offering one. Ask which stage produces which artifact, whether the docking protocol was chosen to match the prior knowledge available, and whether the synthesis request carries its own acceptance criteria. A partner who can answer those three questions has a workflow. A partner who leads with a score has a ranking.
Where the documentation runs out, decide on the artifact. If a peptide table arrives without search parameters, ask for them before docking. If a pose table arrives without its criterion, ask which one was applied. If a specification arrives without a sequence version, ask which molecule you are being asked to test. Those questions cost nothing and settle most of the argument.
MOL Changes supports this workflow at the points where the artifacts are produced: peptide library design with defined length, offset, mutation and control logic, and custom synthesis with a certificate of analysis covering HPLC purity, MS identity and peptide content. If you are scoping a campaign, send us your target, peptide lengths and assay plan, and we will review the feasibility with you.
出版社の開示: MOL Changes はペプチド サービスを提供しており、このトピックに商業的関心を持っています。. サービス範囲と機能に関する記述はサプライヤーの主張です; 特定の構成の可用性とパフォーマンスにはプロジェクト固有の証拠が必要です.
